EYLEA RECEIVES FDA APPROVAL FOR THE TREATMENT OF DIABETIC RETINOPATHY IN PATIENTS WITH DME

Regeneron Pharmaceuticals announced that the FDA has approved Eylea (aflibercept) injection for the treatment of diabetic retinopathy in patients with diabetic macular edema (DME), according to a company news release. In 2014, the FDA granted Eylea breakthrough therapy designation and priority review for the treatment of diabetic retinopathy in patients with DME. Diabetic retinopathy coupled […]

Anuncio publicitario

Leer Más "EYLEA RECEIVES FDA APPROVAL FOR THE TREATMENT OF DIABETIC RETINOPATHY IN PATIENTS WITH DME"